HC
PACB icon

Henshaw Capital’s Pacific Biosciences PACB Stock Holding History

Henshaw Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-48,109
Closed -$180K – 292
2024
Q1 		$180K Buy
48,109
+11,718
+32% +$68.6K 0.01% 282
2023
Q4 		$357K Buy
36,391
+4,958
+16% +$40.5K 0.02% 215
2023
Q3 		$262K Buy
31,433
+12,624
+67% +$144K 0.02% 242
2023
Q2 		$250K Hold
18,809
– – 0.01% 210
2023
Q1 		$218K Hold
18,809
– – 0.01% 229
2022
Q4 		$154K Hold
18,809
– – 0.01% 246
2022
Q3 		$109K Hold
18,809
– – 0.01% 292
2022
Q2 		$83.1K Hold
18,809
– – 0.01% 301
2022
Q1 		$171K Buy
+18,809
New +$217K 0.01% 311

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Henshaw Capital's PACB Position: Q2 2024 in Review

Henshaw Capital sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 48,109 shares — an estimated $180K sold.

Henshaw Capital first reported a position in PACB in Q1 2022 and held it in 9 quarters. The position peaked at $357K in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Henshaw Capital reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Henshaw Capital sold 48,109 Pacific Biosciences shares in Q2 2024, an estimated $180K.
  • Henshaw Capital first reported a position in Pacific Biosciences in Q1 2022 and held it in 9 quarters.
  • Henshaw Capital's Pacific Biosciences position peaked at $357K in Q4 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Henshaw Capital's 13F filing for Q2 2024, filed 28 May 2026.